Premium
P2‐321: COST OF ILLNESS ESTIMATES FOR DEMENTIA IN DENMARK: A REVIEW
Author(s) -
Jørgensen Kasper,
Waldemar Gunhild,
Sørensen Jan
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1000
Subject(s) - dementia , danish , purchasing power parity , health care , indirect costs , medicine , gerontology , environmental health , disease , business , economics , economic growth , accounting , finance , linguistics , philosophy , pathology , exchange rate
disease progression was modeled using equations derived directly from trial data. Changes in antipsychotic medications use upon initiation of AD treatment and following treatment discontinuation were incorporated using data from a published retrospective cohort study. Costs included drug acquisition and monitoring costs, total medical costs and informal care costs associated with caregiver time. Costs were reported in 2013 US dollars. Costs and health outcomes were discounted at 3% per annum. Results: Over 3 years, combination therapy was less costly and more effective when compared with AChEI monotherapy. Combination therapy was associated with a discounted quality-adjusted life-year (QALY) gain of 0.13 per patient. Over 3 years, direct medical and societal discounted costs were reduced by $20,947 and $18,355 per patient, respectively. Reductions in costs were mostly attributable to reductions in the need for institutional care. With combination therapy, patient time at home was increased by an average of 3.99 months, with a reduction of time spent in the most severe stages of the AAIC 2014 Cost-Effectiveness of Memantine ER in the US disease of 2.29 months. One-way sensitivity analyses and probabilistic sensitivity analyses found that combination therapy was less costly and more effective than AChEI monotherapy in almost all scenarios. Conclusions:Memantine ER and AChEI for patients with moderate-to-severe AD is a cost-effective treatment compared to AChEI monotherapy in the US.